![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 19, 2025
Highlights from SABCS featuring new multimodal AI models developed by ECOG-ACRIN and Caris to advance recurrence risk assessment and personalized care in early-stage breast cancer
December 19, 2025
This companion study aims to build a biobank of tumor tissue samples to identify factors driving breast cancer recurrence despite treatment
December 19, 2025
The trials explore potential treatment improvements for different cancer types: bladder, lung, lymphoma, myeloma, and stomach
December 19, 2025
Blood and breast cancer research highlights from the 67th American Society of Hematology Annual Meeting and Exposition, and the San Antonio Breast Cancer Symposium
December 19, 2025
Timely updates on research leaders, presentations at medical meetings and more
November 21, 2025
A recap of the Fall 2025 Group Meeting, trial results from ESMO, and a look ahead to the ASH Annual Meeting and Exposition and the San Antonio Breast Cancer Symposium
November 21, 2025
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2025 Group Meeting
November 21, 2025
In an annual evaluation, 37 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 21, 2025
Compliance guidance for an updated policy that aims to accelerate free public access to research funded by the National Institutes of Health
November 21, 2025
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
November 21, 2025
The latest clinical trial findings in follicular lymphoma, prostate cancer, precision medicine, symptom science, and patient -reported outcomes
November 21, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more